Description: Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, engages in the acquisition, development, and commercialization of branded prescription products for the hospital acute care and gastroenterology markets primarily in the United States. Its principal products include Acetadote, an intravenous formulation of N-acetylcysteine indicated for the treatment of acetaminophen poisoning; Caldolor, an intravenous formulation of ibuprofen for the treatment of pain and fever; and Kristalose, a prescription laxative administered orally for the treatment of constipation. It also develops Hepatoren injection, which is in Phase II clinical development for the treatment of hepatorenal syndrome. The company markets and sells its products through sales representatives and managers. Cumberland Pharmaceuticals, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Home Page: www.cumberlandpharma.com
CPIX Technical Analysis
1600 West End Avenue
Nashville,
TN
37203
United States
Phone:
615 925 3875
Officers
| Name | Title |
|---|---|
| Mr. A. J. Kazimi MBA | Founder, Chairman, Pres & CEO |
| Mr. John Michael Hamm | Sr. Director of Fin. & Accounting and CFO |
| Mr. James Lowrance Herman | Exec. VP of National Accounts & Chief Compliance Officer |
| Ms. Jean W. Marstiller | Sr. VP of Admin. Services & Corp. Sec. |
| Ms. Cindy B. Patton | Sr. Director of Field Marketing |
| Mr. Adam S. Mostafa | Managing Director |
| Mr. Todd M. Anthony | VP of Organizational Devel. |
| Ms. Erin Smith Gull | Sr. Corp. Relations Associate |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.7985 |
| Price-to-Sales TTM: | 0.7933 |
| IPO Date: | 2009-08-11 |
| Fiscal Year End: | December |
| Full Time Employees: | 83 |